LTIMindtree Announces Partnership and Strategic Investment in Voicing.AI, An Agentic AI Solution for Customer Engagement Processes
4.12.2024 06:00:00 EET | Business Wire | Press release
LTIMindtree USA Inc., a wholly owned subsidiary of LTIMindtree [NSE: LTIM, BSE: 540005], a global technology consulting and digital solutions company, announced a partnership, including a strategic investment in Voicing.AI, a next-generation start-up. This partnership aligns with LTIMindtree’s strategy, AI in everything, Everything for AI and AI for Everyone. Voicing.AI’s proprietary technology brings human-like voice capability across more than 20 languages with conversational, contextual, and emotional intelligence, in what is typically referred to as ‘agentic AI’.
LTIMindtree aims to reshape the future of Business Processes by leveraging AI-led platforms. This will enable their clients to optimize costs, reduce risk, enhance user experience, address revenue leakages, and enhance upsell opportunities. LTIMindtree will help clients integrate Voicing.AI with their custom tools, knowledge bases - both structured or unstructured, CRM systems, and leading call management platforms and systems. This Agentic AI technology is fully compliant with SOC2, HIPAA, and multi-layered data security protocols.
You can view the demo video here.
“Our investment with Voicing.AI aims to redefine how businesses interact with their customers through intelligent automation and AI,” said Debashis Chatterjee, CEO and Managing Director, LTIMindtree. “This partnership and investment not only underscore our commitment to innovation but also ensures that LTIMindtree is an early mover in capitalizing on the disruption expected across platform operations.”
“Voicing.AI is fundamentally disrupting the massive customer engagement market by powering new revenue growth, personalizing customer connections, and fostering a human dialogue between a business and its customers. LTIMindtree presented us with a deeply focused comprehensive vision for this Responsible AI transformation and we are excited to partner with them,” said Abhi Kumar, Co-Founder - Voicing.AI. “We look forward to working with LTIMindtree’s global clients to fulfill the growing demand as more enterprises look to automate their platform operations.”
About LTIMindtree:
LTIMindtree is a global technology consulting and digital solutions company that enables enterprises across industries to reimagine business models, accelerate innovation, and maximize growth by harnessing digital technologies. As a digital transformation partner to more than 700 clients, LTIMindtree brings extensive domain and technology expertise to help drive superior competitive differentiation, customer experiences, and business outcomes in a converging world. Powered by 84,000+ talented and entrepreneurial professionals across more than 30 countries, LTIMindtree — a Larsen & Toubro Group company — solves the most complex business challenges and delivers transformation at scale. For more information, please visit https://www.ltimindtree.com/.
About Voicing.AI:
Voicing.AI provides codeless infrastructure for enterprises to build and scale human-like AI voice agents to maximize productivity & business outcomes, with top-tier trust and safety protocols for a Responsible AI. Voicing AI helps enterprises progress with every customer interaction: Sales & Marketing, supercharge your conversion rate by up to 8x by instantly calling inbound leads as soon as they engage with you; Customer Success: enhance your customer care experience by instantly reaching out to customers the moment they request assistance; Listen to Users: improve your feedback collection by instantly reaching out to your users at any interaction. For more information, please visit https://www.voicing.ai/.
View source version on businesswire.com: https://www.businesswire.com/news/home/20241203436754/en/
Contacts
Media Contacts:
Michelle Kumar | Global Media Relations | Michelle.NaliniKumar@ltimindtree.com
Gitanjali Sreepal | Global Media Relations | Gitanjali.sreepal@ltimindtree.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
www.businesswire.com
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Barilla Opens Global Call for Startups Through Good Food Makers 202625.5.2026 12:47:00 EEST | Press release
Barilla Group has opened applications for the 2026 edition of Good Food Makers, its global open innovation program designed to co-develop and test new innovative solutions with startups and innovators inside real industrial environments. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260521973445/en/ Since its launch in 2019, the program has involved more than 1,100 startups from over 50 countries, leading to 26 pilot projects, with over 20 projects currently active thanks to the solutions developed by the program’s alumni. This highlights the program’s role as a concrete platform for industrial scalable innovation. The 2026 edition comes at a pivotal moment for the company, following the launch of BITE (Barilla Innovation & Technology Experience), the new innovation center dedicated to developing the next generation of food products. Within this inspiring premise, Good Food Makers confirms itself as one of the main levers f
JEOL: Sales Launch of the Laser SEM System “LazEdge”25.5.2026 11:16:00 EEST | Press release
JEOL Ltd. (President & CEO: Izumi Oi) has developed the “LazEdge”, an SEM system equipped with a laser processing system, and begins sales on May 25, 2026. Cross-section preparation instruments such as the focused ion beam system (FIB system), are widely used in science and technology fields across research institutes, universities, and industries. In recent years, demand is increasing for a system that can process large-areas at a high speed, while achieving high-quality of the processed surface. “LazEdge” is an instrument integrating JEOL’s SEM with the laser technology proprietary of Hamamatsu Photonics K.K., and enables laser processing inside the specimen chamber of the electron microscope. This system enables high-quality cross-section specimens produced through high-speed, large-area processing to be transferred seamlessly to subsequent analyses, such as SEM observation, elemental analysis, and crystal orientation analysis, without exposure to the external environment. As a resu
TFG-001, A Novel 3D Neural Microtissue Cell Therapy, Demonstrates Superior Functionality and Reinnervation for Parkinson’s Disease25.5.2026 09:00:00 EEST | Press release
TreeFrog Therapeutics, a regenerative medicine biotech company developing next-generation cell therapies, today announced that it will present new preclinical data on TFG-001 at the 7th World Parkinson’s Conference. TFG-001, a 3D neural microtissue cell therapy, demonstrated rapid dopamine release and extensive graft-derived reinnervation across multiple advanced translational Parkinson’s disease models—supporting its potential as a best-in-class candidate. The critical need for reinnervation in Parkinson's disease In Parkinson's disease, an estimated 60–80% of dopaminergic neurons are already lost before motor symptoms even appear. The nigrostriatal pathway degenerates, destroying the essential wiring that connects dopamine-producing neurons to movement control. While chemical dopamine replacements (like levodopa) can manage symptoms, they cannot restore the spatial precision, feedback loops, or dynamic regulation of a healthy brain network. To achieve true functional restoration, it
TFG-001, A Novel 3D Neural Microtissue Cell Therapy, Demonstrates Superior Functionality and Reinnervation for Parkinson’s Disease25.5.2026 09:00:00 EEST | Press release
TreeFrog Therapeutics, a regenerative medicine biotech company developing next-generation cell therapies, today announced that it will present new preclinical data on TFG-001 at the 7th World Parkinson’s Conference. TFG-001, a 3D neural microtissue cell therapy, demonstrated rapid dopamine release and extensive graft-derived reinnervation across multiple advanced translational Parkinson’s disease models—supporting its potential as a best-in-class candidate. The critical need for reinnervation in Parkinson's disease In Parkinson's disease, an estimated 60–80% of dopaminergic neurons are already lost before motor symptoms even appear. The nigrostriatal pathway degenerates, destroying the essential wiring that connects dopamine-producing neurons to movement control. While chemical dopamine replacements (like levodopa) can manage symptoms, they cannot restore the spatial precision, feedback loops, or dynamic regulation of a healthy brain network. To achieve true functional restoration, it
Galderma Receives U.S. FDA Approval for Differin ® Epiduo ® Acne Gel Prescription-to-OTC Switch22.5.2026 19:25:00 EEST | Press release
Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) use in ages 12 years and older, marking a significant Prescription-to-OTC transition in acne care. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260522074280/en/ The U.S. FDA approves Differin® Epiduo® Acne Gel Prescription-to-OTC switch This milestone represents yet another example of Galderma’s unique Integrated Dermatology strategy, demonstrating how proven innovations from its Therapeutic Dermatology portfolio can further strengthen its Dermatological Skincare offerings. The Prescription‑to‑OTC transition highlights Galderma’s scale and expertise in successfully commercializing dermatology innovations across the full spectrum of acne care. With the appro
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom